Biosimilars May Be Impacting Payers’ Medical Benefit Spend

Over the past decade, commercial per-member per-month (PMPM) drug spend under the medical benefit has almost doubled, according to Magellan Rx Management, a division of Magellan Health, Inc.

The company just released the 10th edition of its Medical Pharmacy Trend Report, which also found that 61% of payers were concerned with their medical benefit spend, up from 32% of payers who said this in the inaugural edition of the report.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
April 11

News Briefs: Amylyx Is Withdrawing ALS Drug Relyvrio in U.S., Canada

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
April 11

New FDA Approvals: FDA Approves BeiGene’s Tevimbra

READ MORE
test-tube
April 11

‘Significant Milestone’ Brings New Weapon to Advanced Melanoma Fight

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today